B+
Bull case
25%
Probability
Target price
$45.00
+132.6% vs current
DNLI
Denali TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$31.50
+62.8% vs current
B-
Bear case
15%
Probability
Target price
$18.00
-7.0% vs current
AI sentiment snapshot
Latest data as of 2026-02-26
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Market tone is cautiously constructive: analysts show a material upside bias with median/mean targets above the current price, while some firms maintain lower targets reflecting downside risk [#SERP-1][#SERP-6]. Newsflow and periodic analyst revisions are the main near-term drivers cited across sources [#SERP-5].
RankAlpha Sentiment AI - 2026-02-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-27eventClinical development milestone/readoutHigh impact
Potential mid-stage trial updates or program readouts for Denali's neurodegenerative pipeline could produce outsized moves; timing is uncertain so a conservative date (window end) is used in the absence of a disclosed date [#SERP-8].
2026-05-27catalyst12-month analyst re-rating windowHigh impact
Consensus analyst updates and model revisions over the next 12 months could re-rate the stock; consensus averages cited near 32.86 and median ~ 31.5 [#SERP-1][#SERP-6]. Conservative timing assumed to capture routine updates.
2027-02-26catalystPartnerships / late-stage progress impacting commercial optionalityHigh impact
Business-development deals or late-stage program progression could materially change long-term valuation; assumed out to one year (conservative) given limited public timing [#SERP-5].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-26 • Updated nightlySource: Internal modelMethodology